Application of o8G modified miRNA-7162-5p

The expression of UBA52 genes through o8G modified miRNA-7162-5p promotes UBA52 genes, solves the unsolved mystery of the relationship between miRNA oxidative damage and disease in DS, realizes early diagnosis and potential treatment of DS, and reveals the pathogenesis of Down syndrome. It provides an important basis for personalized medical care.

CN118995908APending Publication Date: 2024-11-22SHENZHEN PEOPLES HOSPITAL +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410968051.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art has failed to effectively explore the existence of o8G in the brain tissue of Down syndrome (DS) and its relationship with disease, and has failed to clarify the application of miRNA-7162-5p in UBA52 gene expression.

Method used

The application of o8G modified miRNA-7162-5p in promoting UBA52 gene expression is used to diagnose and treat DS. By quantitatively detecting the amount of o8G modified miRNA-7162-5p in samples, a diagnostic system and model animal was constructed, and UBA52 gene expression was developed. Regulate control agents to regulate brain development.

Benefits of technology

By analyzing the key differentially modified molecule miR-7162-5p and its target genes, it was found that o8G modification leads to upregulation of UBA52 expression, providing important clues for the onset and progress of DS, helping to understand the molecular mechanisms of the disease, discover biomarkers and develop targeted therapeutic methods. , improves the accuracy and therapeutic effect of early diagnosis of the disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118995908A_ABST
    Figure CN118995908A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biology, and discloses an application of miRNA-7162-5p modified by o8G (o8G). The inventor observes significant disorder of small RNA o8G modification in DS brain tissue, a key difference modification molecule of the small RNA o8G modification is miR-7162-5p, o8G modification of the miR-7162-5p causes up-regulation of UBA52 expression, and the UBA52 is a key gene for DS morbidity and progression. The UBA52 gene can provide important clues about occurrence, development and treatment of diseases. In DS brain tissue development research, the UBA52 gene can provide important clues about occurrence, development and treatment of diseases. The method can help understand the molecular mechanism of diseases, discover new biomarkers, develop targeted therapy methods and guide personalized medical treatment. The UBA52 gene provides a way for deeply knowing DS brain tissue dysplasia for the inventor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the biological field, and specifically relates to the application of o8G-modified miRNA-7162-5p. Background Art

[0002] Down syndrome (DS), the most common chromosomal disorder associated with intellectual disability, is characterized by a range of additional clinical manifestations. Extra copies of chromosome 21, known as trisomy 21, have long been considered as a potential cause of DS. Remarkably, by approximately age 40, nearly all patients with DS develop neuropathological changes typical of Alzheimer's disease, including the presence of beta-amyloid plaques and neurofibrillary tangles. The deleterious effects of oxidative stress on brain development further accelerate aging and contribute to the development of Alzheimer's disease later in life. In patients with DS, oxidative stress significantly contributes to cognitive impairment. However, further studies are needed to elucidate the exact nature of the interrelationship between DS and oxidative stress.

[0003] DS is a clinical manifestation caused by 200 to 300 genes located on chromosome 21, as well as epigenetic factors. DS causes significant changes in gene expression on non-trisomic chromosomes, indicating disruption of downstream transcriptional networks. Studying the trans-actions of simple chromosomal aneuploidies on genome-wide epigenetic patterns has advanced our understanding of basic biological mechanisms and may yield insights relevant to treatment. In terms of pathophysiology, reactive oxygen species (ROS) exert control over a variety of cellular phenotypes by oxidizing biomolecules. Among them, guanine bases in nucleic acids are particularly susceptible to oxidation, forming 8-hydroxyguanine (8-oxoG), which can pair with adenine. The presence of 8-oxoG (o8G) in RNA alters the structural and functional dynamics of RNA-RNA interactions, thereby modulating post-transcriptional regulation. Although both DNA and RNA can react with ROS, RNA has unique properties that make it more susceptible to oxidation. RNA oxidation has a wide range of biological effects, from genetic information transmission to gene expression regulation, and can severely interfere with multiple functions and regulation of coding and noncoding RNAs. Therefore, o8G is not only involved in oxidative damage but also, as an epitranscriptome modification, is involved in the pathophysiological consequences of oxidative stress conditions. However, the presence of o8G in DS brain tissue has remained unexplored to date.

[0004] Recently, oxidation of o8G has been observed in miRNAs, which are regulatory noncoding RNAs that recognize hundreds of target mRNAs by base pairing with the seed region (positions 2-8). By reducing mRNA stability and / or translation, miRNAs repress the expression of their target mRNAs. miRNAs have diverse pathophysiological roles, depending on the function of their targets. Therefore, any alteration in the seed sequence may result in miRNAs targeting different sets of transcripts, leading to redirection of miRNA-mediated functions. In fact, extensive oxidation of miR-184 has been reported to target Bcl-xL and Bcl-w, thereby increasing cardiomyocyte cell death and exacerbating ischemia-reperfusion (IR) injury. This suggests that oxidative damage to miRNAs can alter their biological functions.

[0005] UBA52 (Ubiquitin A-52 Residue Ribosomal Protein Fusion Product 1) is a protein-coding gene. Diseases associated with UBA52 include atrial septal defect and stomatitis. Its associated pathways include PAK-2p34 activated by proteasome-mediated degradation and MyD88-dependent cascade initiated on endosomes. Gene ontology (GO) annotations associated with this gene include structural components of the ribosome. An important paralog of this gene is RPS27A. Summary of the invention

[0006] The purpose of the present invention is to overcome at least one deficiency of the prior art and provide an application of o8G-modified miRNA-7162-5p.

[0007] The technical solution adopted by the present invention is: The first aspect of the present invention provides: The invention relates to the use of o8G-modified miRNA-7162-5p in promoting the expression of UBA52 gene, wherein the use is not for the diagnosis and / or treatment of diseases.

[0008] In some application examples, it is used to promote the expression of UBA52 gene in experimental cells or experimental animals.

[0009] The second aspect of the present invention provides: Application of reagents for quantifying o8G-modified miRNA-7162-5p in the preparation of diagnostic reagents for abnormal brain tissue development.

[0010] In some application examples, the sample detected by the reagent for quantifying o8G-modified miRNA-7162-5p is a blood sample.

[0011] The third aspect of the present invention provides: A diagnostic system comprising: a quantification device for determining the amount of o8G-modified miRNA-7162-5p in a sample; an analysis device for determining the risk of a disease based on the amount of o8G-modified miRNA-7162-5p in a sample; The result output device is used to output the analysis result of the analysis device.

[0012] In some examples of the diagnostic system, the disease is a maldevelopmental disorder of brain tissue.

[0013] In some examples of diagnostic systems, the sample is a blood sample.

[0014] A fourth aspect of the present invention provides: A method for constructing a model animal with high expression of the UBA52 gene, comprising injecting o8G-modified miRNA-7162-5p into the animal.

[0015] In some examples of the construction methods, the animal is a mouse, a rat, a rabbit, a sheep, a pig, a monkey, or a dog.

[0016] A fifth aspect of the present invention provides: Application of UBA52 gene expression regulating agents in the preparation of brain development interference agents.

[0017] In some application examples, the UBA52 gene expression regulatory agent is an RNAi or promoter regulator targeting the UBA52 gene.

[0018] A sixth aspect of the present invention provides: A method for constructing a brain development abnormality model animal comprises administering a UBA52 gene expression regulating agent into the animal.

[0019] In some examples of the construction method, the UBA52 gene expression regulatory agent is an RNAi or promoter regulator targeting the UBA52 gene.

[0020] The beneficial effects of the present invention are: The inventors observed significant dysregulation of o8G modification of small RNA in DS brain tissue. By analyzing the key differentially modified molecule miR-7162-5p and its target gene, the inventors found that o8G modification of miR-7162-5p led to upregulation of UBA52 expression, which is a key gene for the onset and progression of DS. In the study of DS brain tissue development, the newly discovered UBA52 gene can provide important clues about the occurrence, development and treatment of the disease. It can help understand the molecular mechanism of the disease, discover new biomarkers, develop targeted treatments, and guide personalized medicine. The UBA52 gene provides the inventors with a way to gain a deeper understanding of the abnormal development of DS brain tissue. In the future, it is expected that gene editing technology (such as CRISPR / Cas9) can be used to knock out or insert specific genes in experimental animals to mimic the development of the disease, which is crucial for studying the function of genes in the disease. The expression pattern of the key gene UBA52 (such as quantitative expression or the presence of mutations) can be used as a diagnostic marker for DS, which helps to improve the accuracy of early diagnosis of the disease. Changes in UBA52 gene expression may be associated with the severity or prognosis of the disease, thereby guiding treatment decisions and predicting treatment effects. For the UBA52 gene, drugs can be designed to target the protein it encodes to achieve a therapeutic effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 Comparative analysis of gene expression patterns and chromosome distribution in brain tissue of Down syndrome fetuses. A. Volcano plot illustrating the distribution of differentially expressed genes. B. Heat map showing the clustering pattern of differentially expressed genes. C. Chromosome localization showing the distribution of differentially expressed genes in the genome. D. Bar graph showing the count of differentially expressed genes on each chromosome.

[0022] Figure 2 are key regulatory genes in DS fetal brain tissue. A. Venn diagram describing differentially expressed genes in different brain regions of DS fetuses. DFC: dorsolateral prefrontal cortex, OFC: orbitofrontal cortex, CBC: cerebellar cortex, VFC: ventrolateral prefrontal cortex, ITC: inferior temporal cortex, HIP: hippocampus. B. Heatmap of gene expression clustering and chromosomal localization with significant differences in 4 or more brain regionsC. Venn diagram showing differentially expressed genes in DS brain tissue at different developmental stages. D. Heatmap of gene expression clustering and chromosomal localization of differentially expressed genes shared by fetal, infant, child, and adult DS brain tissueE. Identification and chromosomal localization of key genes in DS fetal brain tissue.

[0023] Figure 3 It is the result of abnormal oxidative stress and small RNA o8G modification remodeling in DS brain tissue.

[0024] Figure 4is the o8G modification level of small RNA in DS brain tissue. A. Volcano plot showing the differential modification status of small RNAs B. Cluster heat map of the clustering pattern of differentially modified small RNAs. C. Quantitative PCR results of MeRIP analysis.

[0025] Figure 5 UBA52 is a key gene in DS and is regulated by o8g-modified miRNA-7162-5p. A. Intersection Venn diagram of target genes and differentially expressed genes of miRNA-7162-5p and o8g-modified miRNA-7162-5p in DS brain tissue B. Expression levels of differentially expressed miRNA-7162-5p and o8g-modified miRNA-7162-5p target genes. C. Enrichment analysis of o8g-modified differentially expressed miRNA-7162-5p target genes in GO and KEGG pathways D. Identification and analysis of hub genes for differential expression of o8g-modified miRNA-7162-5p target genes. DETAILED DESCRIPTION

[0026] The technical solution of the present invention is further explained below in conjunction with experiments.

[0027] Sample collection This study included patients with DS at 19 to 22 weeks of gestation. DS was confirmed by genetic diagnosis. No known chromosomal and genetic abnormalities were found in the control group. All research procedures followed the principles of ethics and responsibility, strictly adhered to the principles of the Declaration of Helsinki, and complied with relevant experimental regulations and legislation. This study was approved by the Medical Ethics Committee of Shenzhen People's Hospital with the approval number LL-KY-2019591. All participants in this study signed a written informed consent. Brain tissue was then obtained, quickly frozen, and stored at -80°C.

[0028] Sample preparation and sequencing RNA-Seq After total RNA was extracted, quality control and quantification were performed using agarose gel electrophoresis and Nanodrop. Subsequently, rRNA was removed from the sample using a specific kit. mRNA was enriched using oligo(dT) magnetic beads. The RNA sequencing library was constructed using a kit, including RNA fragmentation, reverse transcription using random primers to generate first-strand cDNA, synthesis of second-strand cDNA containing dUTP, end repair and a-tailing of double-stranded cDNA, Illumina adapter ligation, and PCR amplification to obtain the final library. The constructed library was quality assessed using Agilent 2100, quantified by qPCR, and sequenced using an Illumina NovaSeq6000 sequencer.

[0029] Arraystarhuman o8G small RNA transcriptome array The Arraystar Human o8G small RNA epitranscriptome array was used in this study. For quality assurance, RNA samples were quantified using a NanoDrop ND-1000 spectrophotometer, and RNA integrity was assessed using a Bioanalyzer 2100 or gel electrophoresis. Each total RNA sample (1-5 μg) was immunoprecipitated with 4 μg of anti-8-hydroxyguanine antibody (MAB3560) and 1 mg of DynabeadsTM M-280 sheep anti-mouse IgG (Invitrogen, 11201D) in 500 μL RIP buffer. The modified RNA generated by the immunoprecipitated magnetic beads was called "IP", while the unmodified RNA was recovered from the supernatant as "Sup". The "IP" and "Sup" were labeled with Cy5 and Cy3 enzymes, respectively, using the standard protocol of Arraystar. The labeled RNAs were then combined and hybridized with the Arraystar Human Small RNA Modification Microarray (8x15K, Arraystar). The resulting arrays were scanned in dual-color channels using an AgilentScanner G2505C.

[0030] Data processing RNA-Seq The raw sequencing data generated by the Illumina NovaSeq 6000 undergoes sequencing quality control (QC) to assess its suitability for subsequent data analysis. After QC, the trimmed data obtained through preprocessing and filtering steps (including the removal of adapter sequences and short fragments from reads) are aligned to the reference genome. The alignment results are then statistically analyzed, such as evaluating the alignment ratio, rRNA and mtRNA content, and sequencing bias on genes. The purpose of these analyses is to determine the suitability of the alignment results for subsequent data analysis. Subsequent analysis includes a series of studies, including gene and transcript expression quantification, analysis based on gene expression levels, selection of differentially expressed genes, and significant enrichment analysis of GO functions and pathways. To aid data exploration, various visualization views such as scatter plots, volcano plots, and cluster plots are generated.

[0031] Arraystarhuman o8G small RNA transcriptome array The acquired array images were analyzed using Agilent Feature Extraction software (version 11.0.1.1). The raw intensities of the immunoprecipitate (IP, cy5-labeled) and supernatant (Sup, cy3-labeled) were normalized using the mean of the spike-in RNA intensity on a log2 scale. After normalization, probe signals with the Present (P) or Marginal (M) QC flags were retained in at least three of the nine samples. Multiple probes corresponding to the same small RNA (miRNA / tsRNA (tRF & tiRNA) / pre-miRNA) were integrated into one RNA level. The “o8G abundance” was assessed based on the normalized intensity of the cy5-labeled IP (modified RNA). The fold difference (FC) threshold and statistical significance (p-value) were applied to determine the differentially o8G-modified RNAs between the two compared groups. The o8G modification heatmap was generated using R software to visualize the o8G modification pattern between samples.

[0032] Datasets from the GEO database The inventors obtained data on DS human brain tissue from the GEO database. Gene expression datasets were obtained from the Affymetrix GPL5175 platform with accession number GSE59630. The dataset included 116 samples from 8 different brain regions, including 58 DS patients and 58 healthy controls, ranging in age from 16 weeks postpartum to 42 years old. The R program was used to identify genes that showed differential expression patterns between DS and healthy control samples. Differential expression analysis was performed using the limma package. Genes with p values ​​less than 0.05 and |FC| greater than 1.5 were considered differentially expressed genes (DEGs).

[0033] MeRIP-qPCR analysis MeRIP-qPCR detects the level of o8G modification of individual small RNA molecules. To begin the process, the inventors supplemented the tube containing magnetic beads and the remaining RNA sample with affinity-purified anti-8-hydroxyguanine antibody (MAB3560) or DynabeadsTMM-280 sheep anti-mouse IgG (Invitrogen, 11201D). The mixture was then combined with RNase inhibitors and incubated overnight at 4°C.

[0034] The beads were washed three times with 300 µl IP buffer (composed of 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.1% NP-40), twice with wash buffer (composed of 50 mM NaCl, 100 mM Tris-HCl, pH7.4, and 0.1% NP-40), and once with elution buffer (composed of 100 mM Tris-HCl, pH 7.4, 1 mM EDTA, and 0.05% SDS). 4 µl of protease and 2 µl of RNAse inhibitor were added to the beads. The resulting lysate and IP samples were then treated with a mixture of phenol, chloroform, and isoamyl alcohol. Subsequently, the supernatant containing RNA from the lysate was labeled “supernatant,” while the RNA obtained from the IP was labeled “MeRIP.” Finally, small RNAs were extracted using the phenol-chloroform method and analyzed by qPCR.

[0035] The qPCR program included an initial incubation at 95°C for 10 min, followed by denaturation at 95°C for 10 s, and annealing / extension at 60°C for 60 s for 40 cycles. Each qPCR was repeated three times using three biological replicates. Small RNAs derived from MeRIP were quantified using the 2^-ΔΔCt method relative to non-immunoprecipitated input mRNA.

[0036] PPI construction and screening of key genes In the inventors' study, the inventors used the STRING online tool, which is specifically used to predict protein-protein interactions (PPIs), to construct a PPI network consisting of selected genes. Genes with scores ≥ 0.4 in the STRING database were selected to build a network model, and the network model was visualized using Cytoscape (v3.8.0) software. In the co-expression network, the maximum clique centrality (MCC) algorithm is considered to be the most effective method for identifying hub nodes. To calculate the MCC of each node, the inventors used CytoHubba, a plug-in incorporated into Cytoscape. It is worth noting that in this study, the top 10 genes in the MCC value were considered to be hub genes, indicating that they play a key role in the network.

[0037] result: Differential gene expression profiles and chromosome distribution in DS fetal brain tissue In order to study the differences in gene expression profiles and chromosome distribution in DS fetal brain tissue, the inventors performed RNA-Seq analysis on the collected DS brain tissue samples and control brain tissue samples. The analysis found that there were 160 up-regulated genes and 143 down-regulated genes in DS brain tissue, such as Figure 1 As shown in A. Figure 1The hierarchical clustering heat map in B shows the unique gene expression patterns observed. In addition, examination of the chromosomal localization of the 303 differentially expressed genes showed that these genes were distributed on chromosomes 1 to 22 and chromosome X (excluding chromosome Y), as shown in Figure 2. Figure 1 C. It is noteworthy that the differentially expressed genes on chromosomes 13, 18, and 21 were upregulated in DS brain tissue, while the differentially expressed genes on chromosome 20 were downregulated in DS brain tissue. Chromosomes 6 and 9 had the largest number of differentially expressed genes, with 33 genes each, followed by chromosome 21, with 32 genes. Figure 1 D. The inventors' research results emphasize that the abnormal gene expression in DS fetal brain tissue is not limited to chromosome 21, but is manifested on multiple chromosomes.

[0038] Key regulatory genes affecting DS fetal brain tissue After the initial analysis, the inventors continued to conduct a comprehensive examination of the differentially expressed genes in DS fetal brain tissue. To achieve this goal, the inventors integrated data from the GSE59630 dataset and intersected the differentially expressed genes in DS fetal brain tissue with genes that showed different expression patterns in different brain regions, such as Figure 2 As shown in A. Therefore, the inventors identified 22 differentially expressed genes, which showed significant expression changes in ≥4 brain regions, such as Figure 2 B. Of these 22 genes, 14 are located on chromosome 21, and the remaining 8 are located on other chromosomes. The 303 differentially expressed genes identified in DS fetal brain tissue were further compared with the differentially expressed genes in DS brain tissue at different stages of development in the GSE59630 dataset. The analysis showed that 12 genes showed significant differential expression in DS fetal period, infancy, childhood and adulthood, such as Figure 2 CD. It is noteworthy that among the 12 genes that consistently showed differential expression throughout the growth and development stages of DS, 1 / 3 were located on chromosomes other than chromosome 21. Finally, the inventors used Cytoscape to study the key genes in DS fetal brain tissue. It is noteworthy that the top 10 core genes are all located on chromosomes other than chromosome 21. For example, the top-ranked core gene UBA52 was found on chromosome 19.

[0039] Abnormal oxidative stress and changes in small RNA o8G modification in DS brain tissue To gain a deeper understanding of the molecular mechanism of DS in fetal brain tissue, the inventors performed KEGG pathway enrichment analysis on the differentially expressed genes. The results showed that signaling pathways related to brain diseases were significantly enriched, including Parkinson's disease, Huntington's disease, neurodegeneration-multiple disease pathway, prion disease, and amyotrophic lateral sclerosis. In addition, the inventors observed the involvement of oxidative stress-related signaling pathways, such as oxidative phosphorylation and HIF-1 signaling pathways ( Figure 3 A). These findings were further confirmed by GSEA analysis, which showed significant differences in oxidative phosphorylation pathways between DS and control brain tissues ( Figure 3 B). Oxidative stress plays a key role in regulating the occurrence of o8G modification of small RNA molecules. To further explore this, the inventors conducted a comprehensive analysis of o8G modification of small RNA in DS fetal brain tissue ( Figure 3 C). The results of principal component analysis (PCA) showed that there were significant differences in the levels of o8G-modified small RNAs in DS fetal brain tissues and control fetal brain tissues ( Figure 3 D). Subsequently, the inventors conducted statistical analysis on the number of miRNAs, pre-miRNAs and tsRNAs, as well as the number of o8g differentially modified miRNAs, pre-miRNAs and tsRNAs ( Figure 3 E). The inventors found 2244 miRNAs, 1275 pre-miRNAs, and 3591 tsRNAs. Among them, 885 miRNAs, 1134 pre-miRNAs, and 1088 tsRNAs had significant o8G modification. These findings provide strong evidence for abnormal oxidative stress levels and significant remodeling of small RNA o8G modification in DS brain tissue.

[0040] In addition, the inventors also visually demonstrated differentially modified small RNAs. Figure 4 A is the volcano plot of differentially modified small RNAs. Figure 4 B is a cluster heat map of differentially modified small RNAs. In order to verify the inventors' chip data, the inventors selected several significantly differentially modified small RNAs for MeRIP qPCR validation, and the results were consistent with the chip data. In DS brain tissue, the inventors observed that the o8G modification level of miRNA-7162-5p was upregulated, while the o8G modification level of miRNA-4664-3p, pre-miRNA-143, and pre-miRNA-548am was downregulated.

[0041] Regulatory role of O8G modification of miRNA-7162-5p in the progression of DS o8G modification has the potential to induce changes in miRNA target genes. To elucidate this mechanism, the inventors used miDB and TargetScan to predict the target genes of miR-7162-5p and o8G-modified miR-7162-5p. The predicted target genes were then intersected with the inventors' RNA-Seq results to identify 10 significantly differentially expressed target genes of miRNA-7162-5p and 36 significantly differentially expressed target genes of o8G-modified miR-7162-5p in DS brain tissue ( Figure 5 A). The complete set of differentially expressed target genes Figure 5 B. In order to gain a deeper understanding of the functions of the 36 differentially expressed target genes of o8g-modified miR-7162-5p, the inventors performed Gene Ontology (GO) and KEGG pathway enrichment analysis ( Figure 5 C). Notably, the inventors identified several pathways associated with DS, including "transcriptional regulation of RNA polymerase II promoter", "protein N-linked glycosylation", "ribosome", "cytoplasmic small ribosomal subunit", "cytoplasmic large ribosomal subunit", and "SH3 domain binding". In addition, to identify the key genes associated with DS in this group of genes, the inventors performed core gene enrichment analysis using Cytoscape, and UBA52 was the top ranked gene closely associated with DS.

[0042] discuss The inventors conducted a comprehensive analysis of gene expression and small RNA o8G modifications in brain tissue of fetuses with trisomy 21 and age-matched controls. The inventors' study established a new framework for studying the development of the fetal brain with trisomy 21. This work helped the inventors understand the differences in gene expression between trisomy 21 and euploid control brains, revealing three key aspects.

[0043] First, the inventors demonstrated that the dysregulated genes were not limited to chromosome 21 but were distributed throughout the genome ( Figure 1 Importantly, most of the genes strongly associated with trisomy 21 are located outside chromosome 21 (Figure 2).

[0044] Second, our findings confirmed the presence of abnormalities in oxidative stress pathways in fetal brain tissue with trisomy 21, further emphasizing their role in the disease ( FIG3 ).

[0045] Third, the inventors discovered significant o8G modification abnormalities in trisomy 21 fetal brain tissue (Figures 4-5). These dysregulated o8G-modified small RNAs play crucial regulatory roles, providing novel and unbiased insights into the multiple biological processes affected during trisomy 21 brain development and maturation. Through this innovative perspective on trisomy 21 brain development, the inventors' research revealed new and powerful abnormalities in gene expression associated with small RNA o8G modifications. These findings provide valuable insights into the complex mechanisms underlying the pathogenesis of trisomy 21 and open up avenues for future research and therapeutic interventions.

[0046] The inventors present strong evidence to support the presence of abnormal small RNA o8G modifications in fetal brain tissues with trisomy 21, revealing the underlying mechanisms of the disease. The inventors' studies not only identified changes in small RNA o8G modifications, but also explored their effects on target gene expression, providing valuable insights into the regulation of genome-wide gene dysregulation in trisomy 21. These findings suggest that there are significant differences between trisomy 21 and euploid fetal brain tissues at the molecular and functional levels. These changes may contribute to the developmental delays and lifelong intellectual disabilities seen in patients with trisomy 21. By identifying these close similarities and understanding the functional consequences of these abnormal modifications, the inventors have gained a deeper understanding of the complex mechanisms underlying the pathogenesis of trisomy 21. This new understanding of the molecular and functional aspects of trisomy 21 lays the foundation for further studies to unravel the complexity of the disease. In addition, this knowledge may drive the development of targeted interventions and therapies, ultimately improving the quality of life for patients with trisomy 21.

[0047] We observed that there was considerable variation in both the number and identity of gene alterations in different brain regions in individuals with trisomy 21 (Fig. 2A-B). Furthermore, our studies revealed temporal changes in the expression profiles of trisomy 21-specific genes (Fig. 2C-D, Fig. S3). Collectively, these findings suggest that the neurobiology of trisomy 21 cannot be summarized by a single static set of dysregulated genes or gene networks. Rather, the complex spatiotemporal dynamics of such perturbations play a critical role throughout development and into adulthood. Indeed, in our study of a limited number of trisomy 21 samples, genes on chromosome 21 showed significant upregulation compared with genes on other chromosomes (Fig. 1C-D). Furthermore, we identified the functional roles played by trisomy 21-associated genes in different brain regions and at different stages of brain tissue development. These profiles of expression changes provide an important foundation for the design and implementation of targeted therapeutic strategies. By focusing on specific biological processes and relevant brain regions during the corresponding developmental period, interventions can be developed to address the unique challenges posed by trisomy 21.

[0048] Reactive oxygen species play a key role in controlling a variety of cellular phenotypes by oxidizing biomolecules (7). Among these biomolecules, guanine bases in nucleic acids are particularly susceptible to oxidation, generating 8-oxo-7,8-dihydroguanine, which can base pair with adenine. In addition to causing oxidative damage, 8-oxo-dG also acts as an epigenetic modifier, affecting transcriptional regulatory elements and other epigenetic modifications. By virtue of its ability to form o8G•A base pairs, o8G can alter RNA-RNA structural and functional interactions, thereby redirecting post-transcriptional regulation. Elevated levels of oxidative stress can lead to damage to lipids, proteins, DNA, and other molecules, thereby amplifying potential mechanisms leading to disease onset (12). In addition, altered oxidative stress may also contribute to the neuropathology observed in age-related degenerative diseases (13-15). In addition, individuals with trisomy 21 have an increased risk of developing Alzheimer's disease in adulthood. The inventors' findings raise the intriguing prospect that aberrant oxidative stress and dysregulated small RNA o8G modification may contribute to the Alzheimer's disease-like pathology seen in trisomy 21. This observation is consistent with the well-established view that oxidative stress is a key mechanism in Alzheimer's disease. Therefore, investigating the role of small RNA o8G modification during development and aging will be an area of ​​focus for future research.

[0049] The inventors' studies have elucidated the regulatory function of o8G-modified miR-7162-5p in regulating the expression of the UBA52 gene, a key gene involved in the pathogenesis of trisomy 21 (Figure 2, Figure 5). UBA52 has been implicated in various pathological conditions. For example, in cases of traumatic brain injury, changes in both UBA52 mRNA and protein levels have been documented. In addition, in the early stages of Parkinson's disease, UBA52 plays a key role in HSP90 ubiquitination and neurodegenerative signaling pathways. The role of UBA52 during embryonic development has also been noted, with mice lacking UBA52 showing reduced protein synthesis, cell cycle arrest, and cell death. Notably, studies have shown that protein ubiquitination levels are significantly reduced in human cell lines associated with trisomy 21 syndrome. Ubiquitin consists of 76 amino acids and is encoded by four genes: UBB, UBC, UBA52, and RPS27a. Down-regulation of UBA52 expression in fetal brain tissue with trisomy 21 may lead to altered ubiquitination levels. Therefore, it is crucial to study the respective roles of small RNA o8G modification and UBA52-mediated ubiquitination as well as other regulatory mechanisms in future studies.

[0050] The inventors' study revealed for the first time the regulatory epigenetic effects occurring in brain tissue of patients with trisomy 21. These results are of great significance for revealing the pathogenesis and treatment strategies of trisomy 21, as well as for clarifying the underlying mechanisms of other human developmental disorders, neuropsychiatric diseases, and chromosomal and subchromosomal apolyploidy diseases.

[0051] The above is a further detailed description of the present invention, which should not be regarded as a limitation on the specific implementation of the present invention. For ordinary technicians in the technical field to which the present invention belongs, simple deduction or replacement without departing from the concept of the present invention is within the protection scope of the present invention.

Claims

1. Application of o8G-modified miRNA-7162-5p in promoting UBA52 gene expression, which is not used for diagnosis and / or treatment of diseases.

2. The use according to claim 1, It is characterized in that It is used to promote the expression of UBA52 gene in experimental cells or experimental animals.

3. Application of reagents for quantifying o8G-modified miRNA-7162-5p in the preparation of diagnostic reagents for abnormal brain tissue development.

4. The use according to claim 3, It is characterized in that The sample for the reagent for quantifying o8G-modified miRNA-7162-5p is a blood sample.

5. A diagnostic system, include: a quantification device for determining the amount of o8G-modified miRNA-7162-5p in a sample; an analysis device for determining the risk of a disease based on the amount of o8G-modified miRNA-7162-5p in a sample; The result output device is used to output the analysis result of the analysis device.

6. The diagnostic system according to claim 5, It is characterized in that The disease is an abnormal development of brain tissue.

7. A method for constructing a model animal with high expression of UBA52 gene, It is characterized in that It involves injecting o8G-modified miRNA-7162-5p into animals.

8. The construction method according to claim 7, It is characterized in that The animals are mice, rats, rabbits, sheep, pigs, monkeys and dogs.

9. Application of UBA52 gene expression regulating agents in the preparation of brain development interference agents.

10. A method for constructing a model animal of brain development abnormality, It is characterized in that The method comprises administering a UBA52 gene expression regulating agent into an animal.